Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to CU20100248ApriorityCriticalpatent/CU20100248A7/en
Publication of CU20100248A7publicationCriticalpatent/CU20100248A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se relaciona con compuestos que inhiben la función de la quinasa de adhesión focal, con los procesos para prepararlos, las composiciones farmacéuticas que los contienen como ingrediente activo, su uso como medicamentos para tratar enfermedades como el cáncer en animales de sangre caliente como el ser humano.The present invention relates to compounds that inhibit the function of focal adhesion kinase, with the processes for preparing them, pharmaceutical compositions containing them as active ingredient, their use as medicaments for treating diseases such as cancer in warm-blooded animals such as the human being
Compounds derived from pyrrolo pyridine carboxamides, jak2 inhibitors; pharmaceutical composition comprising them; use in the treatment of myeloproliferative diseases or cancer, such as polycythemia vera, essential thrombocytopenia, multiple myeloma, among others.
DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES